期刊文献+

Global progress against cancer—challenges and opportunities 被引量:2

Global progress against cancer—challenges and opportunities
下载PDF
导出
摘要 The last ten years have seen remarkable progress in cancer research.However,despite significant breakthroughs in the understanding,prevention,and treatment of cancer,the disease continues to affect millions of people worldwide.Cancer’s complexity compounded with financial,policy and regulatory roadblocks has slowed the rate of progress being made against cancer.In this paper,we review a few of the most recent breakthroughs that are fueling medical advances and bringing new hope for patients affected by this devastating disease.We also address the challenges facing us and the opportunities to accelerate future progress against cancer.The efforts of the American Association for Cancer Research(AACR)to address the cancer burden already extend beyond the borders of the United States of America.The AACR is committed to increasing its efforts to stem the tide of cancer worldwide by promoting innovative programs,strategies,and initiatives for cancer researchers and all those engaged in cancer-related biomedical sciences around the world. The last ten years have seen remarkable progress in cancer research. However, despite significant breakthroughs in the understanding, prevention, and treatment of cancer, the disease continues to affect millions of people worldwide. Cancer's complexity compounded with financial, policy and regulatory roadblocks has slowed the rate of progress being made against cancer. In this paper, we review a few of the most recent breakthroughs that are fueling medical advances and bringing new hope for patients affected by this devastating disease. We also address the challenges facing us and the opportunities to accelerate future progress against cancer. The efforts of the American Association for Cancer Research (AACK) to address the cancer burden already extend beyond the borders of the United States of America. The AACR is committed to increasing its efforts to stem the tide of cancer worldwide by promoting innovative programs, strategies, and initiatives for cancer researchers and all those engaged in cancer-related biomedical sciences around the world.
出处 《Cancer Biology & Medicine》 SCIE CAS CSCD 2013年第4期183-186,共4页 癌症生物学与医学(英文版)
关键词 癌症 医学科学 世界范围 研究人员 复杂性 破坏性 Collaboration prevention translational research genetics genomics epigenetics immunotherapy
  • 相关文献

参考文献12

  • 1Ferlay J,Shin HR,Bray F,Forman D Mathers C Parkin DM. Estimates of worldwide burden of cancer in,2008:GLOBOCAN,2008[J].International Journal of Cancer,2010.2893-2917.
  • 2Bray F,Jemal A,Grey N,Ferlay J Forman D. Global cancer transitions according to the Human Development Index(2008-2030):a population-based study[J].Lancet Oncology,2012.790-801.
  • 3Hanahan D,Weinberg AR. hTe hallmarks of cancer[J].Cell,2000.57-70.
  • 4Hanahan D,Weinberg AR. Hallmarks of cancer:the next generation[J].Cell,2011.646-674.
  • 5Vogelstein B,Papadopoulos N,Velculescu VE,Zhou S Diaz LA Kinzler KW. Cancer genome landscapes[J].Science,2013.1546-1558.
  • 6Garraway LA,Lander ES. Lessons from the cancer genome[J].Cell,2013.17-37.
  • 7Socinski MA,Bondarenko I,Karaseva NA,Makhson AM Vynnychenko I Okamoto I. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as ifrst-line therapy in patients with advanced non-small-cell lung cancer:ifnal results of a phase III trial[J].Journal of Clinical Oncology,2012.2055-2062.
  • 8Von Hoff DD,Ervin TJ,Arena FP,Chiorean EG, Infante JR, Moore MJ,. Results of a randomized phase III trial(MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates[J].Journal of Clinical Oncology,2013.4005.
  • 9Tan J,Cang S,Ma Y,Petrillo RL Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents[J].J Hematol Oncol,2010.5.
  • 10Juergens AR,Wrangle J,Vendetti FP,Murphy SC Zhao M Coleman B. Combination epigenetic therapy has effcacy in patients with refractory advanced non-small cell lung cancer[J].Cancer Discov,2011.598-607.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部